← Leaderboards
Brian P Sorrentino
St. Jude Children'S Research Hospital
$13,809,294
Attributed
$13,809,294
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.8M · FY2005–14$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$26,152,720 · 8
By mechanism
P01$22,420,345 · 6
R01$3,261,625 · 1
R21$470,750 · 1
Top collaborators
No co-investigators on record.
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Charles G. Mullighan$25,123,215
- Arthur W. Nienhuis$5,923,134
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyHematopoietic Stem CellsSickle Cell AnemiaBaseFundingBone Marrow TransplantationMacaca MulattaResearch StudyImmunologic Deficiency SyndromesSaint Jude Children&AposS Research HospitalClinical TrialsStem CellsCellsVectorCellular TransductionProtocols DocumentationTransplantationResourcesReconstitutionCell PhysiologyResearch PersonnelHematopoieticPrograms
Grant awards (46)
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders$2,555,299
P01 · FY2014 · HL · contact PI
Stem Cell Core$365,043
P01 · FY2014 · HL · contact PI
Administrative Core$365,043
P01 · FY2014 · HL · contact PI
Evaluation of self-inactivating lentiviral vectors for treating SCID-X1 patients$365,043
P01 · FY2014 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders$2,394,432
P01 · FY2013 · HL · contact PI
Stem Cell Core$342,062
P01 · FY2013 · HL · contact PI
Evaluation of self-inactivating lentiviral vectors for treating SCID-X1 patients$342,062
P01 · FY2013 · HL · contact PI
Administrative Core$342,061
P01 · FY2013 · HL · contact PI
Library Screening for Novel Enhancer Blockers Derived from Human T Lymphocytes$208,250
R21 · FY2013 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders$2,488,242
P01 · FY2012 · HL · contact PI
Stem Cell Core$355,462
P01 · FY2012 · HL · contact PI
Administrative Core$355,462
P01 · FY2012 · HL · contact PI
Evaluation of self-inactivating lentiviral vectors for treating SCID-X1 patients$355,461
P01 · FY2012 · HL · contact PI
Library Screening for Novel Enhancer Blockers Derived from Human T Lymphocytes$262,500
R21 · FY2012 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders$2,436,444
P01 · FY2011 · HL · contact PI
Stem Cell Core$348,064
P01 · FY2011 · HL · contact PI
Administrative Core$348,064
P01 · FY2011 · HL · contact PI
Evaluation of self-inactivating lentiviral vectors for treating SCID-X1 patients$348,064
P01 · FY2011 · HL · contact PI
Lentiviral Gene Therapy for Sickle Cell Disease and Immunodeficiency Disorders$2,469,009
P01 · FY2010 · HL · contact PI
Stem Cell Core$352,716
P01 · FY2010 · HL · contact PI
Administrative Core$352,716
P01 · FY2010 · HL · contact PI
Evaluation of self-inactivating lentiviral vectors for treating SCID-X1 patients$352,716
P01 · FY2010 · HL · contact PI
CORE--ANIMAL MODELS$466,052
P01 · FY2008 · HL · contact PI
The Role of ABC Transporters in Stem Cells$355,568
R01 · FY2008 · HL · contact PI
In Vivo Selection of Transduced Hematopoietic Stem Cells$305,351
P01 · FY2008 · HL · contact PI
CORE--ANIMAL MODELS$475,111
P01 · FY2007 · HL · contact PI
The Role of ABC Transporters in Stem Cells$355,568
R01 · FY2007 · HL · contact PI
In Vivo Selection of Transduced Hematopoietic Stem Cells$312,917
P01 · FY2007 · HL · contact PI
CORE--ANIMAL MODELS$477,201
P01 · FY2006 · HL · contact PI
The Role of ABC Transporters in Stem Cells$366,188
R01 · FY2006 · HL · contact PI
In Vivo Selection of Transduced Hematopoietic Stem Cells$315,981
P01 · FY2006 · HL · contact PI
CORE--ANIMAL MODELS$464,222
P01 · FY2005 · HL
The Role of ABC Transporters in Stem Cells$375,000
R01 · FY2005 · HL
In Vivo Selection of Transduced Hematopoietic Stem Cells$309,069
P01 · FY2005 · HL
The Role of ABC Transporters in Stem Cells$467,177
R01 · FY2004 · HL
CORE--ANIMAL MODELS$450,936
P01 · FY2004 · HL
In Vivo Selection of Transduced Hematopoietic Stem Cells$300,657
P01 · FY2004 · HL
The Role of ABC Transporters in Stem Cells$454,976
R01 · FY2003 · HL
The Role of ABC Transporters in Stem Cells$440,197
R01 · FY2002 · HL
IN VIVO SELECTION OF TRANSDUCED HEMATOPOIETIC STEM CELLS$126,320
P01 · FY2002 · HL
CORE--ANIMAL MODELS$126,320
P01 · FY2002 · HL
The Role of ABC Transporters in Stem Cells$446,951
R01 · FY2001 · HL
CORE--ANIMAL MODELS$126,320
P01 · FY2001 · HL
IN VIVO SELECTION OF TRANSDUCED HEMATOPOIETIC STEM CELLS$126,320
P01 · FY2001 · HL
CORE--ANIMAL MODELS$202,053
P01 · FY2000 · HL
IN VIVO SELECTION OF TRANSDUCED HEMATOPOIETIC STEM CELLS$202,050
P01 · FY2000 · HL